Table 3. Prognostic factors for OS by univariate analysis for patients with metastatic or recurrent ESCC (n=187).

Variables	Patients (n)	Median OS (months)	1-year OS rate (%)	2-year OS rate (%)	P
Gender
Female	72	12.0	48.0	9.2	0.956
Male	115	12.0	46.1	12.2
Age (Years)
≤60	92	14.0	53.9	13.0	0.314
>60	95	11.0	40.3	8.8
First line treatment
Radiotherapy	70	11.0	46.1	10.3	0.711
Surgery	117	11.0	41.7	8.8
Weight loss
Yes	90	13.0	38.9	4.2	0.012
No	97	11.0	53.4	17.0
Tumor location
Upper and middle	92	11.0	42.1	7.5	0.203
Lower	95	13.0	51.3	14.1
Serum albumin level
≤42.1	88	11.0	43.2	11.6	0.642
>42.1	99	14.0	50.2	10.5
BMI
≤20.4	95	11.0	42.2	9.4	0.789
>20.4	92	13.0	51.6	13.2
Tumor length
≤5 cm	46	13.0	50.8	11.5	0.845
>5 cm	141	11.0	45.6	10.0
Tumor
Metastasis	125	11.0	42.9	9.7	0.234
Recurrent	49	12.0	48.1	12.2
Metastasis and recurrent	13	10.0	15.4	0
Chemotherapy regimens
S1	108	11.0	43.3	5.9	0.071
Paclitaxel	79	12.0	46.5	16.7
Treatment response
CR+PR	67	16.0	75.5	26.1	<0.001
SD+PD	120	10.0	29.9	2.1
NRS
< 3	89	14.0	57.1	16.8	0.002
≥3	98	11.0	36.7	5.4